Latest Market Entry News

Hazer Group has entered a binding six-year strategic alliance with global engineering leader KBR to exclusively market and license its methane pyrolysis technology, targeting the ammonia and methanol sectors. This partnership aims to accelerate commercialisation, expand global reach, and materially de-risk Hazer’s business plan.

Neurotech International has reported excellent safety and tolerability for its lead drug NTI164 in 28-day GLP toxicology studies, paving the way for regulatory submissions and longer-term clinical development.

Wide Open Agriculture Limited has clarified that its recently signed offtake and distribution agreement with Univar Solutions China carries no immediate financial impact, outlining a phased market entry and sales timeline.

DUG Technology reported a 23% surge in software revenue and a 15% rise in EBITDA for FY25-Q3, underpinned by strong services order growth and strategic expansion into Brazil.

Zimi Limited confirms $1.42 million in open orders with key distributor GSM Electrical, backed by shareholder approval for up to $6 million in future sales. The company also advances its commercial market ambitions through a new partnership with Zencontrol.

Memphasys Limited has completed a pivotal Phase III trial confirming its Felix™ System as best-in-class for sperm separation, while advancing regulatory and commercial efforts in China and Brazil supported by fresh capital.

Australian Dairy Nutritionals Limited reported a record $736k revenue from nutritional powders in Q3 FY25, driven by its new Future brand launch in China and expanding sales in Vietnam. The company’s strategic partnerships and premium product positioning signal a pivotal shift in its growth trajectory.

Ovanti Limited has taken decisive steps to accelerate its US Buy Now Pay Later (BNPL) market entry, appointing an interim CEO and securing a pivotal 20-year licensing agreement with BNPLPay Protocol that offers low-cost funding and a significant revenue share.

Cardiex reports strong early sales momentum for its CONNEQT Pulse device with approximately 3,000 units sold or contracted since its mid-January launch, supported by innovative app features and operational efficiencies. Despite regulatory delays in the US pharma sector and tariff challenges, the company is positioned for scalable growth and category leadership in preventative cardiovascular care.

Terragen Holdings has launched its new probiotic products for ruminants, initiated multiple key trials including methane mitigation and crop yield studies, and secured a US patent allowance, positioning itself for global market expansion.

Clarity Pharmaceuticals reports a robust cash position and strategic refocus on its lead prostate cancer asset, Cu-SAR-bisPSMA, supported by multiple FDA Fast Track designations and advancing clinical trials.

Stakk Limited reports a staggering 2,533% quarter-on-quarter increase in annual recurring revenue to $472k, fueled by its acquisition of US-based Radical DBX and rapid expansion in Embedded Finance across Australia and the US.